SOLIGENIX, INC.;DONINI, OREOLA;ROZEK, ANNETT;LEE, JACKSON;NORTH, JOHN;ABRAMS, MICHAEL
发明人:
DONINI, OREOLA,ROZEK, ANNETT,LEE, JACKSON,NORTH, JOHN,ABRAMS, MICHAEL
申请号：
CA2923553
公开号：
CA2923553A1
申请日:
2014.08.11
申请国别(地区):
CA
年份:
2015
代理人:
摘要：
Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and coiitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis "window" with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and / or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.
